Cibc World Markets Corp Has $6.93 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Cibc World Markets Corp increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 14.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,645 shares of the medical research company’s stock after acquiring an additional 11,873 shares during the period. Cibc World Markets Corp’s holdings in Edwards Lifesciences were worth $6,933,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of EW. Wellington Management Group LLP grew its position in Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares in the last quarter. Jennison Associates LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $555,939,000. Assenagon Asset Management S.A. boosted its holdings in Edwards Lifesciences by 475.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after purchasing an additional 3,506,886 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth $213,844,000. Finally, Jacobs Levy Equity Management Inc. raised its holdings in Edwards Lifesciences by 239.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after buying an additional 2,606,950 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $70.31 on Wednesday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a market cap of $41.33 billion, a P/E ratio of 10.09, a PEG ratio of 4.82 and a beta of 1.12. The company’s 50-day simple moving average is $71.61 and its 200 day simple moving average is $70.35.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 51,303 shares of company stock worth $3,715,776 over the last three months. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of analyst reports. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Barclays lifted their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Truist Financial reaffirmed a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, The Goldman Sachs Group lifted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.